Compass Therapeutics (CMPX) Invested Capital (2023 - 2025)
Historic Invested Capital for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to $209.6 million.
- Compass Therapeutics' Invested Capital rose 5145.67% to $209.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $209.6 million, marking a year-over-year increase of 5145.67%. This contributed to the annual value of $125.2 million for FY2024, which is 1568.96% down from last year.
- Latest data reveals that Compass Therapeutics reported Invested Capital of $209.6 million as of Q3 2025, which was up 5145.67% from $93.2 million recorded in Q2 2025.
- In the past 5 years, Compass Therapeutics' Invested Capital ranged from a high of $209.6 million in Q3 2025 and a low of $93.2 million during Q2 2025
- In the last 3 years, Compass Therapeutics' Invested Capital had a median value of $148.5 million in 2023 and averaged $148.4 million.
- Examining YoY changes over the last 5 years, Compass Therapeutics' Invested Capital showed a top increase of 5145.67% in 2025 and a maximum decrease of 3620.5% in 2025.
- Compass Therapeutics' Invested Capital (Quarter) stood at $148.5 million in 2023, then dropped by 15.69% to $125.2 million in 2024, then soared by 67.38% to $209.6 million in 2025.
- Its last three reported values are $209.6 million in Q3 2025, $93.2 million for Q2 2025, and $110.3 million during Q1 2025.